All
Heavy silicone oil proves effective, safe for persistent full-thickness macular holes
December 31st 2022The use of heavy silicone oil tamponade in secondary surgery for persistent full-thickness macular holes is a safe and efficient surgical method. Best-corrected visual acuity and minimum linear diameter before surgery may be indicators for anatomical success.
Researchers find COVID impacts depth perception
December 23rd 2022The study, co-led by Griffith University’s Menzies Health Institute and South Korea’s Center for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technology, aims to understand how SARS-CoV-2 affects the eyes and whether it could serve as a virus infection route.
Collaboration focusing on boosting patient access, participation in ophthalmology clinical trials
December 20th 2022Parexel teams with MyEyeDr. to leverage MyEyeDr.’s 850+ offices across the United States to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are.
Researchers: Retinal cells may possess ability to protect themselves from diabetic retinopathy
December 16th 2022Investigators have found that cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.
2023: What awaits ophthalmology in the year ahead
December 12th 2022As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Gene therapy offers improved retinal sensitivity, visual function, and mobility
December 11th 2022In a multicenter phase 1/2 safety study conducted in the US and UK, researchers conducted a dose-escalation trial of AAV5-RPGR that included low, intermediate, and high doses of the gene therapy administered to 3, 4, and 3 adults, respectively.
Aviceda clears key IND toxicity hurdle with positive safety profile in non-human primates
December 8th 2022The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with geographic atrophy secondary to AMD that addresses the underlying causes of the disease.